Ann: CLTX CAR T data shows regional control of tumour recurrence, page-24

I would not go so far as saying that he is too thin.


We have a dedicated CEO and managing director.

Viralytics was successful.

IMU is an ASX success story.

CHM is showing exciting potential at this early stage.

Hoppers next venture, Radiopharm Theranostics, will have good direction from the beginning. There is no doubt that this is what he is good at - a track record of setting up promising and successful biotechnology companies that have net positive results for humanity and for share holders.

Presently the CHM ship is in more of an auto pilot mode, it does require management and input, but at the end of the day only the data will tell the tru doth.

if CHM were to go belly up, at the least one could say that there was a positive impact to scientific knowledge of cancer treatment. That is why I am here. Personally, I am tired of investing in companies who simply dig up dirt or drill for gas etc., where overall net benifit could be damaging to climate, plants and animals.

these days, It's so hard to filter out speculative ASX listed companies who are not lifestyle scam dream pump and dump operations in terms of extracting money from mum's and dad's to fill the pockets of clever scam artists.....